Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
12/11/2008
Trade Name:
PegIntron
Generic or Proper Name (*):
Peginterferon alfa-2b
Indications Studied:
Co-administered with ritonavir to treat chronic hepatitis C in patients 3 years of age and older with compensated liver disease previously untreated with interferon alpha
Therapeutic Category:
Antiviral
Ages Studied:
3 - 17 years
Study #:
1
Study Type:
Efficacy/Safety/Pharmacokinetic/Tolerability
Study Design:
Open Label/Traditional Pharmacokinetic
No Patients:
107
No Centers:
22
No Countries:
9
BPCA(B), PREA(P):
P
-
-